🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Belzutifan VHL RCC HK Prospective Registry

Recruitingn/aAges 18 Years - anyAllChinese University of Hong Kong
NCT07554508 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the Belzutifan's efficacy, drug safety, disease course, and the health-economic impact of the treatment to Von Hippel-Lindau (VHL) syndrome.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients (age 18 or above) with confirmed VHL-spectrum disease through clinical and/or genetic diagnosis. * The patient decided to use Belzutifan for their treatment. Exclusion Criteria: * Tumour requiring immediate resection. * Pregnancy or unwillingness to use contraception if of childbearing potential. * Uncontrolled comorbidities (e.g., active infection, severe cardiopulmonary disease).
💊

What it tests

  • Not listed
📍

Where

1 site
Prince of Wales Hospital
Shatin, Hong Kong
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy